{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:08:14Z","timestamp":1790399294436,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000032","name":"Institute of Infection and Immunity","doi-asserted-by":"publisher","award":["360929"],"award-info":[{"award-number":["360929"]}],"id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000032","name":"Institute of Infection and Immunity","doi-asserted-by":"publisher","award":["353953"],"award-info":[{"award-number":["353953"]}],"id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"crossref","award":["000"],"award-info":[{"award-number":["000"]}],"id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00262-020-02555-2","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:03:00Z","timestamp":1585890180000},"page":"1423-1436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade"],"prefix":"10.1007","volume":"69","author":[{"given":"Isobel S.","family":"Okoye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-2009","authenticated-orcid":false,"given":"Shokrollah","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"2555_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01215","author":"IS Okoye","year":"2017","unstructured":"Okoye IS, Houghton M, Tyrrell L, Barakat K, Elahi S (2017) Coinhibitory receptor expression and immune checkpoint blockade: Maintaining a balance in CD8+T cell responses to chronic viral infections and cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.01215","journal-title":"Front Immunol"},{"key":"2555_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","volume":"10","author":"SD Blackburn","year":"2009","unstructured":"Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DAA, Wherry EJ (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10:29\u201337","journal-title":"Nat Immunol"},{"issue":"12","key":"2555_CR3","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","volume":"3","author":"DS Thommen","year":"2015","unstructured":"Thommen DS, Schreiner J, Muller P et al (2015) Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res 3(12):1344\u20131355","journal-title":"Cancer Immunol Res"},{"key":"2555_CR4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918","journal-title":"Lancet Oncol"},{"key":"2555_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-3-319-22539-5_9","volume":"167","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Flaherty CR, Postow MA (2016) Checkpoint blockade for the treatment of advanced melanoma. Cancer Treat Res 167:231\u2013250","journal-title":"Cancer Treat Res"},{"key":"2555_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1353076","author":"OW Hakenberg","year":"2017","unstructured":"Hakenberg OW (2017) Nivolumab for the treatment of bladder cancer. Expert Opin Biol Ther. https:\/\/doi.org\/10.1080\/14712598.2017.1353076","journal-title":"Expert Opin Biol Ther"},{"key":"2555_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"2555_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(16)30098-5","journal-title":"Lancet Oncol"},{"key":"2555_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw226","author":"P Economopoulou","year":"2016","unstructured":"Economopoulou P, Agelaki S, Perisanidis C, Giotakis EI, Psyrri A (2016) The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdw226","journal-title":"Ann Oncol"},{"key":"2555_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3907","author":"P Bachireddy","year":"2015","unstructured":"Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ (2015) Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/nrc3907","journal-title":"Nat Rev Cancer"},{"key":"2555_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0454-7","author":"ZW Myint","year":"2017","unstructured":"Myint ZW, Goel G (2017) Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-017-0454-7","journal-title":"J Hematol Oncol"},{"key":"2555_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:486\u2013499","journal-title":"Nat Rev Immunol"},{"key":"2555_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.394","author":"KA Marrone","year":"2016","unstructured":"Marrone KA, Ying W, Naidoo J (2016) Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.394","journal-title":"Clin Pharmacol Ther"},{"key":"2555_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"key":"2555_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"2555_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.09.002","author":"B El Osta","year":"2017","unstructured":"El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC (2017) Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.09.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"2555_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190\u2013209","journal-title":"Eur J Cancer"},{"key":"2555_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000377650","volume":"38","author":"S Wozniak","year":"2015","unstructured":"Wozniak S, Mackiewicz-Wysocka M, Krokowicz L, Kwinta L, Mackiewicz J (2015) Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab\u2014case report. Oncol Res Treat 38:105\u2013108","journal-title":"Oncol Res Treat"},{"key":"2555_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","volume":"28","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP (2016) Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28:254\u2013263","journal-title":"Curr Opin Oncol"},{"key":"2555_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-208102","author":"T Ahmed","year":"2015","unstructured":"Ahmed T, Pandey R, Shah B, Black J (2015) Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2014-208102","journal-title":"BMJ Case Rep"},{"key":"2555_CR21","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang T-O et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193\u20133198","journal-title":"J Clin Oncol"},{"key":"2555_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"key":"2555_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9606-0","author":"K Harmankaya","year":"2011","unstructured":"Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, Binder M (2011) Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. https:\/\/doi.org\/10.1007\/s12032-010-9606-0","journal-title":"Med Oncol"},{"key":"2555_CR24","first-page":"339","volume":"130","author":"A Pawarode","year":"2017","unstructured":"Pawarode A, D\u2019Souza A, Pasquini MC et al (2017) Phase 2 study of pembrolizumab during lymphodepleted state after autologous hematopoietic cell transplantation in multiple myeloma patients. Blood 130:339","journal-title":"Blood"},{"key":"2555_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.10.009","author":"A Garant","year":"2017","unstructured":"Garant A, Guilbault C, Ekmekjian T, Greenwald Z, Murgoi P, Vuong T (2017) Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.10.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"2555_CR26","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:2872\u20132878","journal-title":"J Clin Oncol"},{"key":"2555_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx380.025","author":"G Mart\u00ednez Bernal","year":"2017","unstructured":"Mart\u00ednez Bernal G, Mezquita L, Auclin E et al (2017) Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx380.025","journal-title":"Ann Oncol"},{"key":"2555_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000477","author":"CM Della Corte","year":"2019","unstructured":"Della Corte CM, Morgillo F (2019) Early use of steroids affects immune cells and impairs immunotherapy efficacy. ESMO Open. https:\/\/doi.org\/10.1136\/esmoopen-2018-000477","journal-title":"ESMO Open"},{"key":"2555_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000457","author":"G Fuc\u00e0","year":"2019","unstructured":"Fuc\u00e0 G, Galli G, Poggi M et al (2019) Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. https:\/\/doi.org\/10.1136\/esmoopen-2018-000457","journal-title":"ESMO Open"},{"key":"2555_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2289","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Stephen Hodi F et al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.73.2289","journal-title":"J Clin Oncol"},{"key":"2555_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.35.15_suppl.9523","author":"JS Weber","year":"2018","unstructured":"Weber JS, Larkin JMG, Schadendorf D et al (2018) Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.9523","journal-title":"J Clin Oncol"},{"key":"2555_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","volume":"6","author":"AJ Giles","year":"2018","unstructured":"Giles AJ, Hutchinson M-KND, Sonnemann HM et al (2018) Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 6:51","journal-title":"J Immunother Cancer"},{"key":"2555_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1500108","author":"R Maxwell","year":"2018","unstructured":"Maxwell R, Luksik AS, Garzon-Muvdi T et al (2018) Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402X.2018.1500108","journal-title":"Oncoimmunology"},{"key":"2555_CR34","doi-asserted-by":"publisher","first-page":"98215","DOI":"10.18632\/oncotarget.21003","volume":"8","author":"I Okoye","year":"2017","unstructured":"Okoye I, Namdar A, Xu L, Crux N, Elahi S (2017) Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. Oncotarget 8:98215\u201398232","journal-title":"Oncotarget"},{"key":"2555_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nm.2422","volume":"17","author":"S Elahi","year":"2011","unstructured":"Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, McElrath MJ, Horton H (2011) Protective HIV-specific CD8(+) T cells evade T(reg) cell suppression. Nat Med 17:989\u2013995","journal-title":"Nat Med"},{"key":"2555_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48826-6","author":"A Ganesan","year":"2019","unstructured":"Ganesan A, Ahmed M, Okoye I et al (2019) Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-48826-6","journal-title":"Sci Rep"},{"key":"2555_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173:945\u2013954","journal-title":"J Immunol"},{"key":"2555_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J et al (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science (80-). https:\/\/doi.org\/10.1126\/science.aaf1292","journal-title":"Science (80-)"},{"key":"2555_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00760.x","author":"U Lorenz","year":"2009","unstructured":"Lorenz U (2009) SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00760.x","journal-title":"Immunol Rev"},{"key":"2555_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107591","author":"DTY Yu","year":"1974","unstructured":"Yu DTY, Clements PJ, Paulus HE, Peter JB, Levy J, Barnett EV (1974) Human lymphocyte subpopulations. Effect of corticosteroids. J Clin Investig. https:\/\/doi.org\/10.1172\/JCI107591","journal-title":"J Clin Investig"},{"key":"2555_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.04.041","author":"C Libert","year":"2014","unstructured":"Libert C, Dejager L (2014) How steroids steer T cells. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2014.04.041","journal-title":"Cell Rep"},{"key":"2555_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.21.2.176","author":"EW Boland","year":"1962","unstructured":"Boland EW (1962) Clinical comparison of the newer anti-inflammatory corticosteroids. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.21.2.176","journal-title":"Ann Rheum Dis"},{"key":"2555_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-015-0103-2","author":"K Xing","year":"2015","unstructured":"Xing K, Gu B, Zhang P, Wu X (2015) Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: An insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunol. https:\/\/doi.org\/10.1186\/s12865-015-0103-2","journal-title":"BMC Immunol"},{"key":"2555_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.154","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Johnson BA, Lutz ER, Laheru DA, Jaffee EM (2017) Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/nrc.2016.154","journal-title":"Nat Rev Cancer"},{"key":"2555_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.25","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/nrclinonc.2016.25","journal-title":"Nat Rev Clin Oncol"},{"key":"2555_CR46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190738","author":"A Tokunaga","year":"2019","unstructured":"Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD, Nishikawa H (2019) Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20190738","journal-title":"J Exp Med"},{"key":"2555_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s000180050403","author":"M Xia","year":"1999","unstructured":"Xia M, Gasser J, Feige U (1999) Dexamethasone enhances CTLA-4 expression during T cell activation. Cell Mol Life Sci. https:\/\/doi.org\/10.1007\/s000180050403","journal-title":"Cell Mol Life Sci"},{"key":"2555_CR48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.it.2006.01.007","volume":"27","author":"RJ Salmond","year":"2006","unstructured":"Salmond RJ, Alexander DR (2006) SHP2 forecast for the immune system: fog gradually clearing. Trends Immunol 27:154\u2013160","journal-title":"Trends Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02555-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-020-02555-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02555-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T19:14:11Z","timestamp":1617390851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-020-02555-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2555"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02555-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"30 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The appropriate Institutional Review Boards at the University of Alberta approved the studies, IRB #Pro00046064.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study participants gave written informed consent to participate in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}